SEC Tracker
Get the app

Coya Therapeutics COYA

Coya Therapeutics reports Q3 2026 financial results and trial updates.

Coya Therapeutics (COYA) filed an 8-K with the SEC on Nov 10, 2026, 8:02 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash and cash equivalents of $35.8 million as of September 30, 2026.
  2. R&D expenses increased to $8.6 million for Q3 2026 from $2.9 million in Q3 2025.
  3. Net loss of $10.6 million for Q3 2026 compared to $2.1 million in Q3 2025.
  4. Completed enrollment of 137 participants in the Phase 2/3 ALSTARS trial for Coya 302.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Coya Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.